Compare ANDE & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | AMPH |
|---|---|---|
| Founded | 1947 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | N/A | 2014 |
| Metric | ANDE | AMPH |
|---|---|---|
| Price | $53.97 | $25.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $58.33 | $31.00 |
| AVG Volume (30 Days) | 289.8K | ★ 368.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.13 | ★ 2.27 |
| Revenue | ★ $11,595,817,000.00 | $723,305,000.00 |
| Revenue This Year | $6.47 | $1.35 |
| Revenue Next Year | $3.36 | $5.10 |
| P/E Ratio | $25.26 | ★ $11.14 |
| Revenue Growth | ★ 2.19 | N/A |
| 52 Week Low | $31.03 | $20.39 |
| 52 Week High | $54.20 | $45.39 |
| Indicator | ANDE | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 42.84 |
| Support Level | $49.14 | $25.22 |
| Resistance Level | $53.32 | $27.84 |
| Average True Range (ATR) | 1.43 | 0.80 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 93.32 | 2.56 |
Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.